Cambrian Bio is a clinical-stage drug development company building the medicines that will modernize healthcare in the 21st century. Our focus lies in creating innovative therapeutics designed to prevent diseases and lengthen healthspan—the period of life spent in good health.
As a Distributed Development Company (or DisCo), Cambrian is advancing multiple scientific breakthroughs, each targeting a biological driver of aging. Our approach is to develop interventions that treat specific diseases first, then deploy them as preventative medicines to improve quality of life/overall quality of life as we age.
To date, we have more than a dozen programs (PipeCos) in our pipeline, including Amplifier Therapeutics (developing a peripherally restricted pan-AMPK activator for the treatment of cardiometabolic diseases), Tornado Therapeutics (developing safer, more effective mTOR inhibitors for extended healthspan), and our latest addition, Telos Biotech (enhancing cell therapies to overcome senescence and exhaustion). We also has programs focused on Women’s Health and Aging (Oviva Therapeutics), Fibrosis (Isterian Biotech), and cellular engineering (Vita Therapeutics).
-
Industry
-
Biotechnology Research
-
Company size
-
11-50 employees
-
Headquarters
-
New York, New York
-
Type
-
Privately Held
-
Founded
-
2019
-
Specialties
-
Biotech, Longevity, Longevity Science, Aging, Aging Biology, Geroscience, Healthspan, Disease Prevention, Healthcare, Pharma, innovation, and Science